Point72 Asset Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$376K Sell
4,700
-8,400
-64% -$693K ﹤0.01% 3264
2025
Q4
$1.12M Sell
13,100
-21,200
-62% -$1.74M ﹤0.01% 2809
2025
Q3
$2.67M Sell
34,300
-176,000
-84% -$13.8M ﹤0.01% 1330
2025
Q2
$16.4M Buy
+210,300
New +$15.7M 0.03% 566
2024
Q2
Sell
-79,200
Closed -$7.57M 2018
2024
Q1
$7.57M Buy
79,200
+60,000
+313% +$5.04M 0.02% 825
2023
Q4
$1.46M Hold
19,200
﹤0.01% 1297
2023
Q3
$1.33M Buy
19,200
+19,000
+9,500% +$1.53M ﹤0.01% 1243
2023
Q2
$18.9K Buy
+200
New +$17.4K ﹤0.01% 1794
2018
Q2
Sell
-300,000
Closed -$14M 1030
2018
Q1
$14M Sell
300,000
-540,300
-64% -$23.5M 0.06% 356
2017
Q4
$31.6M Buy
+840,300
New +$30.8M 0.14% 202
2016
Q1
Sell
-436,200
Closed -$11.5M 760
2015
Q4
$11.5M Sell
436,200
-463,800
-52% -$12M 0.09% 251
2015
Q3
$21.3M Buy
+900,000
New +$21.7M 0.17% 182

Other funds holding EW

Point72 Asset Management's EW Position: Q1 2026 in Review

Point72 Asset Management increased its Edwards Lifesciences (EW) stake by 311% in Q1 2026, buying an estimated $114M and bringing the position to 1,826,537 shares worth $146M. The position accounts for 0.19% of the portfolio, ranked #101.

Point72 Asset Management first reported a position in EW in Q3 2014 and has held it in 34 quarters since. The position peaked at $284M in Q1 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Point72 Asset Management held 1,826,537 shares of Edwards Lifesciences worth $146M as of Q1 2026.
  • Point72 Asset Management bought 1,382,170 Edwards Lifesciences shares in Q1 2026, an estimated $114M.
  • Edwards Lifesciences made up 0.19% of Point72 Asset Management's portfolio in Q1 2026, its #101 holding.
  • Point72 Asset Management first reported a position in Edwards Lifesciences in Q3 2014 and has held it in 34 quarters since.
  • Point72 Asset Management's Edwards Lifesciences position peaked at $284M in Q1 2024.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.